ZIA BC 011659 (ZIA) | |||
---|---|---|---|
Title | Deciphering the efficacy of posttransplant cyclophosphamide in haplo transplant | ||
Institution | NCI, Bethesda, MD | ||
Principal Investigator | Kanakry, Christopher | NCI Program Director | N/A |
Cancer Activity | N/A | Division | CCR |
Funded Amount | $711,613 | Project Dates | null - null |
Fiscal Year | 2018 | Project Type | Intramural |
Research Topics w/ Percent Relevance | Cancer Types w/ Percent Relevance | ||
Bone Marrow Transplantation (100.0%) Cancer (100.0%) |
Leukemia (100.0%) | ||
Research Type | |||
Systemic Therapies - Discovery and Development Systemic Therapies - Clinical Applications |
|||
Abstract | |||
We are developing an MHC-haploidentical allogeneic bone marrow transplantation model that parallels human treatment and can be used to decipher the immunologic impact of post-transplantation cyclophosphamide (PTCy). We are studying the impact of this therapy on clinical endpoints (survival, graft-versus-host disease, weight); accompanying these studies is a detailed characterization of the immunologic and histopathologic changes associated with this approach. Once the mechanisms by which PTCy prevents GVHD uncovered, we will use this understanding as a basis to explore how to refine this BMT approach clinically towards the clinical goals of further reducing graft-versus-host disease, ensuring reliable engraftment with minimal conditioning, and serving as a platform for other therapies to reduce relapse. We also are exploring the impact of PTCy on human T cells in mixed lymphocyte cultures with the goal of improving our understanding of the immunologic impact of PTCy in order to improve clinical outcomes. Lastly, we have begun a study to investigate if antigen-specific cellular therapy can be safely and effectively integrated with haplo BMT using PTCy. |